Database Study of Treatment Burden and State of Medical Care with Existing Treatments in Patients with Congenital Hemophilia A
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Emicizumab (Primary) ; Factor VIII inhibitor bypassing fraction
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms HIKOBOSHI
- Sponsors Chugai Pharmaceutical
- 07 Nov 2022 Status changed from not yet recruiting to completed.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Mar 2021 New trial record